Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design ...

Management Goals of management of an open corneal injury are to ensure a watertight globe to prevent hypotony and infection, reestablish original anatomy as much as possible, and lastly, restore ...

Corneal perforation was observed in a patient treated with cabozantinib for advanced renal cell carcinoma, suggesting a potential ocular adverse effect. The patient's corneal ulcer recurred and ...

(A) Left cornea with a paracentral fusiform perforation, flat anterior chamber with iris-endothelium touch, oval stromal infiltrate with edema, and prominent radial Descemet folds. (B) Transient ...

ABSTRACT: Pellucid marginal degeneration (PMD) is the second-most common noninflammatory corneal degeneration after keratoconus. We report a case of a 42-year-old Saudi male who presented with ...

ABSTRACT: Pellucid marginal degeneration (PMD) is the second-most common noninflammatory corneal degeneration after keratoconus. We report a case of a 42-year-old Saudi male who presented with ...

Neuropathic corneal pain is a debilitating condition characterized by persistent, severe eye pain caused by nerve damage, impacting a significant number of patients worldwide. OKYO Pharma's urcosimod ...